Cognition Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Cognition Therapeutics Stock-Based Compensation Growth & History (CGTX)
Cognition Therapeutics's stock-based compensation was $2.1M for fiscal 2025.
View full Cognition Therapeutics company overviewCognition Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.1M | −$1.7M | −44.32% |
| 2024 | 2024-12-31 | $3.7M | −$606,000 | −13.92% |
| 2023 | 2023-12-31 | $4.4M | $782,000 | +21.89% |
| 2022 | 2022-12-31 | $3.6M | −$1.6M | −31.08% |
| 2021 | 2021-12-31 | $5.2M | $4.7M | +991.16% |
| 2020 | 2020-12-31 | $475,000 | — | — |
Cognition Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $319,000 | −$302,000 | −48.63% |
| Q1 2026 | 2026-03-31 | $330,000 | −$256,000 | −43.69% |
| Q4 2025 | 2025-12-31 | $358,000 | −$176,000 | −32.96% |
| Q3 2025 | 2025-09-30 | $522,000 | −$374,000 | −41.74% |
| Q2 2025 | 2025-06-30 | $621,000 | −$526,000 | −45.86% |
| Q1 2025 | 2025-03-31 | $586,000 | −$585,000 | −49.96% |
| Q4 2024 | 2024-12-31 | $534,000 | −$537,000 | −50.14% |
| Q3 2024 | 2024-09-30 | $896,000 | −$175,000 | −16.34% |
| Q2 2024 | 2024-06-30 | $1.1M | $122,000 | +11.90% |
| Q1 2024 | 2024-03-31 | $1.2M | −$16,000 | −1.35% |
| Q4 2023 | 2023-12-31 | $1.1M | $169,000 | +18.74% |
| Q3 2023 | 2023-09-30 | $1.1M | $294,000 | +37.84% |
| Q2 2023 | 2023-06-30 | $1.0M | $133,000 | +14.91% |
| Q1 2023 | 2023-03-31 | $1.2M | $186,000 | +18.58% |
| Q4 2022 | 2022-12-31 | $902,000 | −$4.0M | −81.66% |
| Q3 2022 | 2022-09-30 | $777,000 | $705,000 | +979.17% |
| Q2 2022 | 2022-06-30 | $892,000 | $798,000 | +848.94% |
| Q1 2022 | 2022-03-31 | $1.0M | $903,000 | +921.43% |
| Q4 2021 | 2021-12-31 | $4.9M | — | — |
| Q3 2021 | 2021-09-30 | $72,000 | −$57,000 | −44.19% |
| Q2 2021 | 2021-06-30 | $94,000 | — | — |
| Q1 2021 | 2021-03-31 | $98,000 | — | — |
| Q3 2020 | 2020-09-30 | $129,000 | — | — |
Cognition Therapeutics stock-based compensation trends
Over the last five fiscal years, Cognition Therapeutics's stock-based compensation increased from $475,000 to $2.1M, a change of $1.6M. The latest reported quarter, Q2 2026, shows $319,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cognition Therapeutics source filings ↗